SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Jacobsen Rikke Kart)
 

Search: WFRF:(Jacobsen Rikke Kart) > Study protocol of t...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Kampmann, Freja BachFrederiksberg Hospital (author)

Study protocol of the InterVitaminK trial : A Danish population-based randomised double-blinded placebo-controlled trial of the effects of vitamin K (menaquinone-7) supplementation on cardiovascular, metabolic and bone health

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • 2023

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:30144d51-36ff-4d29-bb62-bff0b71d9af1
  • https://lup.lub.lu.se/record/30144d51-36ff-4d29-bb62-bff0b71d9af1URI
  • https://doi.org/10.1136/bmjopen-2023-071885DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Introduction Vitamin K has been suggested to have protective effects against progression of vascular calcification and development of cardiovascular disease (CVD). However, few well-powered randomised controlled trials have examined whether vitamin K prevents progression of vascular calcification in individuals from the general population. The aim of the InterVitaminK trial is to investigate the effects of vitamin K supplementation (menaquinone-7, MK-7) on cardiovascular, metabolic, respiratory and bone health in a general ageing population with detectable vascular calcification. Methods and analysis The InterVitaminK trial is a randomised, double-blinded, placebo-controlled, trial. A total of 450 men and women aged 52-82 years with detectable coronary artery calcification (CAC), but without manifest CVD, will be randomised (1:1) to receive daily MK-7 (333 μg/day) or placebo tablets for 3 years. Health examinations are scheduled at baseline, and after 1, 2 and 3 years of intervention. Health examinations include cardiac CT scans, measurements of arterial stiffness, blood pressure, lung function, physical function, muscle strength, anthropometric measures, questionnaires on general health and dietary intake, and blood and urine sampling. The primary outcome is progression of CAC from baseline to 3-year follow-up. The trial has 89% power to detect a between-group difference of at least 15%. Secondary outcomes are bone mineral density, pulmonary function and biomarkers of insulin resistance. Ethics and dissemination Oral MK-7 supplementation is considered safe and has not been found to cause severe adverse events. The Ethical Committee of the Capital Region (H-21033114) approved the protocol. Written informed consent is obtained from all participants and the trial is conducted in accordance with the Declaration of Helsinki II. Both negative and positive findings will be reported. Trial registration number NCT05259046.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Thysen, Sanne MarieFrederiksberg Hospital (author)
  • Nielsen, Camilla Friis BrydeFrederiksberg Hospital (author)
  • Kofoed, Klaus FuglsangUniversity of Copenhagen,Copenhagen University Hospital (author)
  • Køber, LarsCopenhagen University Hospital (author)
  • Pham, Michael Huy CuongCopenhagen University Hospital (author)
  • Vaag, AllanLund University,Lunds universitet,Translationell diabetesforskning,Forskargrupper vid Lunds universitet,Translational Diabetes Research,Lund University Research Groups,Skåne University Hospital,Copenhagen University Hospital(Swepub:lu)med-ava (author)
  • Jørgensen, Niklas RyeUniversity of Copenhagen,Copenhagen University Hospital (author)
  • Petersen, JanneFrederiksberg Hospital,University of Copenhagen (author)
  • Jacobsen, Rikke KartFrederiksberg Hospital (author)
  • Kårhus, Line LundFrederiksberg Hospital (author)
  • Diederichsen, AxelOdense University Hospital (author)
  • Frimodt-Møller, MarieCopenhagen University Hospital (author)
  • Linneberg, AllanFrederiksberg Hospital,University of Copenhagen (author)
  • Frederiksberg HospitalUniversity of Copenhagen (creator_code:org_t)

Related titles

  • In:BMJ Open13:52044-6055

Internet link

Find in a library

  • BMJ Open (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view